Compare COLM & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLM | RCUS |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1997 | 2018 |
| Metric | COLM | RCUS |
|---|---|---|
| Price | $55.24 | $21.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $60.86 | $29.20 |
| AVG Volume (30 Days) | 484.2K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $3,042,478,000.00 | $247,000,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $3.04 | $70.88 |
| P/E Ratio | $17.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $47.48 | $6.79 |
| 52 Week High | $77.97 | $26.40 |
| Indicator | COLM | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 47.73 |
| Support Level | $53.96 | $20.35 |
| Resistance Level | $58.08 | $24.62 |
| Average True Range (ATR) | 1.52 | 1.16 |
| MACD | -0.34 | -0.13 |
| Stochastic Oscillator | 17.17 | 9.33 |
Columbia Sportswear Co makes outdoor and active-lifestyle apparel, footwear, equipment, and accessories that it sells under four primary brands: Columbia, Sorel, Mountain Hardwear, and prAna. The majority of sales are in the United States, but the company also has remarkable sales in its three other geographic segments: Latin American and Asia-Pacific; Europe, Middle East, and Africa; and Canada. The majority of sales are through wholesale channels, including sporting goods and department stores, but the company also operates its own branded stores in each of its geographic segments. It sources products from around the world and uses contract manufacturers outside the United States, predominantly in Asia to manufacture its various products.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.